Skip to content

NAVIDEA BIOPHARMACEUTICALS, INC.

CIK 0000810509

← back to feed
Revenue (TTM)
$65.04K
−87.6% YoY Q3 Nov 2023
Net Income (TTM)
−$14.72M
−29.4% YoY Q3 Nov 2023
EPS Diluted (TTM)
−$0.09
−200.0% YoY Q3 Nov 2023
Gross Margin
-107.4%
Q3 Nov 2023
Operating Margin
-18,345.4%
Q3 Nov 2023
Net Margin
-22,635.7%
Q3 Nov 2023
Free Cash Flow (TTM)
−$8.41M
Q3 Nov 2023
Cash
$3.86M
Q3 Nov 2023
Total Debt
$62.41K
Q3 Nov 2023
Shares Outstanding
100.08M sh
Q3 Nov 2023

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings